• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Clinical value of continuous administration of sorafenib in combination with modified transarterial chemoembolization in patients with unresectable hepatocellular carcinoma.

作者信息

Huang Yong-Hui, Chen Wei, Li Jia-Ping, Chen Bin, Yang Jian-Yong

机构信息

Department of Interventional Radiology, First Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong 510080, China.

出版信息

Chin Med J (Engl). 2013 Jan;126(2):385-6.

PMID:23324295
Abstract
摘要

相似文献

1
Clinical value of continuous administration of sorafenib in combination with modified transarterial chemoembolization in patients with unresectable hepatocellular carcinoma.索拉非尼持续给药联合改良经动脉化疗栓塞术治疗不可切除肝细胞癌患者的临床价值
Chin Med J (Engl). 2013 Jan;126(2):385-6.
2
Sorafenib combined with TACE in advanced primary hepatocellular carcinoma.索拉非尼联合经动脉化疗栓塞术治疗晚期原发性肝细胞癌
Hepatogastroenterology. 2013 Mar-Apr;60(122):305-10. doi: 10.5754/hge12552.
3
Transarterial chemoembolization and sorafenib in patients with intermediate-stage hepatocellular carcinoma: time to enter routine clinical practice?经动脉化疗栓塞术与索拉非尼治疗中期肝细胞癌患者：是时候进入常规临床实践了吗？
Future Oncol. 2015;11(17):2371-3. doi: 10.2217/FON.15.173. Epub 2015 Aug 13.
4
Sorafenib in combination with transarterial chemoembolization improves the survival of patients with unresectable hepatocellular carcinoma: a propensity score matching study.索拉非尼联合经动脉化疗栓塞可提高不可切除肝细胞癌患者的生存率：一项倾向评分匹配研究。
J Dig Dis. 2013 Apr;14(4):181-90. doi: 10.1111/1751-2980.12038.
5
The combination of transcatheter arterial chemoembolization and sorafenib is well tolerated and effective in Asian patients with hepatocellular carcinoma: final results of the START trial.经导管动脉化疗栓塞术联合索拉非尼在亚洲肝细胞癌患者中具有良好的耐受性和疗效：START 试验的最终结果。
Int J Cancer. 2015 Mar 15;136(6):1458-67. doi: 10.1002/ijc.29126. Epub 2014 Sep 16.
6
Sorafenib in combination with transarterial chemoembolization for the treatment of hepatocellular carcinoma.索拉非尼联合经动脉化疗栓塞术治疗肝细胞癌。
Clin Adv Hematol Oncol. 2016 Aug;14(8):585-7.
7
Enhanced therapeutic efficacy of combined use of sorafenib and transcatheter arterial chemoembolization for treatment of advanced hepatocellular carcinoma.索拉非尼联合经导管动脉化疗栓塞治疗晚期肝细胞癌的疗效增强。
Jpn J Clin Oncol. 2014 Aug;44(8):711-7. doi: 10.1093/jjco/hyu068. Epub 2014 May 22.
8
Effects of sorafenib combined with chemoembolization and radiofrequency ablation for large, unresectable hepatocellular carcinomas.索拉非尼联合化疗栓塞和射频消融治疗大的不可切除肝细胞癌的疗效。
Chin Med J (Engl). 2013 Nov;126(22):4270-6.
9
Safety of transarterial chemoembolization plus sorafenib combination treatment in unresectable hepatocellular carcinoma.经动脉化疗栓塞联合索拉非尼治疗不可切除肝细胞癌的安全性
Scand J Gastroenterol. 2010 Apr;45(4):511-2. doi: 10.3109/00365521003628335.
10
Concurrent sorafenib therapy extends the interval to subsequent TACE for patients with unresectable hepatocellular carcinoma.对于不可切除的肝细胞癌患者，同时使用索拉非尼治疗可延长至后续经动脉化疗栓塞术（TACE）的间隔时间。
J Surg Oncol. 2016 May;113(6):672-7. doi: 10.1002/jso.24215. Epub 2016 Mar 14.

引用本文的文献

1
Combination of NK-based immunotherapy and sorafenib against hepatocellular carcinoma.基于自然杀伤细胞的免疫疗法与索拉非尼联合治疗肝细胞癌
Am J Cancer Res. 2021 Feb 1;11(2):337-349. eCollection 2021.
2
Efficacy evaluation of the combination therapy of sorafenib and transarterial chemoembolization for unresectable HCC: a systematic review and meta-analysis of comparative studies.索拉非尼与经动脉化疗栓塞联合治疗不可切除肝癌的疗效评估：一项比较研究的系统评价与荟萃分析
Ann Transl Med. 2020 Apr;8(8):540. doi: 10.21037/atm.2020.02.115.
3
Transarterial chemoembolization plus sorafenib for the management of unresectable hepatocellular carcinoma: a systematic review and meta-analysis.
经动脉化疗栓塞联合索拉非尼治疗不可切除肝细胞癌的系统评价与Meta分析
BMC Gastroenterol. 2018 Sep 4;18(1):138. doi: 10.1186/s12876-018-0849-0.
4
Combination therapy of sorafenib and TACE for unresectable HCC: a systematic review and meta-analysis.索拉非尼与经动脉化疗栓塞术联合治疗不可切除肝细胞癌：一项系统评价与荟萃分析
PLoS One. 2014 Mar 20;9(3):e91124. doi: 10.1371/journal.pone.0091124. eCollection 2014.